MEDICARE DRUG BENEFIT LIMITED PROGRAM COULD CUT COST OF CLINTON PLAN BY $20-$30 BIL., PhRMA CONTENDS; SCALED-BACK PLANS APPEAR TO GAIN FAVOR ON CAPITOL HILL
Executive Summary
The Pharmaceutical Research & Manufacturers of America (PhRMA) continues to push for a scaled-back drug coverage plan for the elderly as a point of departure for a Medicare drug benefit.